Jump to content

2C-T-31

Add links
From Wikipedia, the free encyclopedia

2C-T-31
Clinical data
Other names2,5-Dimethoxy-4-(4-trifluoromethyl­benzylthio)phenethylamine; 4-(4-Trifluoromethyl­benzylthio)-2,5-dimethoxyphenethylamine
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor very weak partial agonist or antagonist
ATC code
  • None
Identifiers
  • 2-[2,5-dimethoxy-4-({[4-(trifluoromethyl)phenyl]methyl}sulfanyl)phenyl]ethan-1-amine
PubChem CID
Chemical and physical data
FormulaC18H20F3NO2S
Molar mass371.42 g·mol−1
3D model (JSmol)
  • FC(F)(F)C1=CC=C(CSC(C(OC)=C2)=CC(OC)=C2CCN)C=C1
  • InChI=1S/C18H20F3NO2S/c1-23-15-10-17(16(24-2)9-13(15)7-8-22)25-11-12-3-5-14(6-4-12)18(19,20)21/h3-6,9-10H,7-8,11,22H2,1-2H3
  • Key:BDOJPUSYOLIGBS-UHFFFAOYSA-N

2C-T-31, also known as 2,5-dimethoxy-4-(4-trifluoromethylbenzylthio)phenethylamine, is a serotonin receptor modulator of the phenethylamine and 2C families.[1][2][3][4] Its properties and effects in humans do not appear to be known.[1] The drug shows affinity for the serotonin 5-HT2A receptor (Ki = 3.8–28 nM) and much lower affinity for the serotonin 5-HT1A and 5-HT2C receptors (Ki = 1,063 nM and 157 nM, respectively).[4][1] It is a very weak partial agonist or antagonist of the serotonin 5-HT2A receptor (EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) = 53 nM (2.8%)) and a moderate-efficacy but very-low-potency partial agonist of the serotonin 5-HT2B receptor (EC50 (Emax) = 3,309 nM (44%)).[4][2] It also shows weak affinity for a number of other targets.[4] The chemical synthesis of 2C-T-31 has been described.[3] 2C-T-31 was first described in the scientific literature by Daniel Trachsel in 2003.[3][1][4]

See also

[edit]

References

[edit]
  1. 1 2 3 4 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. 1 2 Gil-Martins E, Barbosa DJ, Borges F, Remião F, Silva R (June 2025). "Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?". Toxicology Reports. 14 101890. Bibcode:2025ToxR...1401890G. doi:10.1016/j.toxrep.2025.101890. PMC 11762925. PMID 39867514. Drugs containing a 4-benzylthio substituent (2C-T-27, 2C-T-31, and 2C-T-33) presented the highest 5-HT2A affinity but the lowest 5-HT2A activation potency, suggesting that phenethylamines with bulky lipophilic substituents might have 5-HT2 antagonistic effects. [...]
  3. 1 2 3 Trachsel D (2003). "Synthese von neuen (Phenylalkyl)aminen zur Untersuchung von Struktur–Aktivitätsbeziehungen. Mitteilung 2: 4-Thio-substituierte [2-(2,5-Dimethoxyphenyl)ethyl]amine (=2,5-Dimethoxybenzolethanamine)" [Synthesis of new (phenylalkyl)amines for the investigation of structure–activity relationships. Communication 2: 4-thio-substituted [2-(2,5-dimethoxyphenyl)ethyl]amines (=2,5-dimethoxybenzenethanamines)]. Helvetica Chimica Acta. 86 (7): 2610–2619. doi:10.1002/hlca.200390210. ISSN 0018-019X.
  4. 1 2 3 4 5 Luethi D, Trachsel D, Hoener MC, Liechti ME (May 2018). "Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)". Neuropharmacology. 134 (Pt A): 141–148. doi:10.1016/j.neuropharm.2017.07.012. PMID 28720478.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=2C-T-31&oldid=1370133425"